WO2009080788A2 - Agents antibactériens - Google Patents

Agents antibactériens Download PDF

Info

Publication number
WO2009080788A2
WO2009080788A2 PCT/EP2008/068100 EP2008068100W WO2009080788A2 WO 2009080788 A2 WO2009080788 A2 WO 2009080788A2 EP 2008068100 W EP2008068100 W EP 2008068100W WO 2009080788 A2 WO2009080788 A2 WO 2009080788A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
halo
alkyl
hydroxy
compound
Prior art date
Application number
PCT/EP2008/068100
Other languages
English (en)
Other versions
WO2009080788A3 (fr
Inventor
Jacques Poupaert
Martine Prevost
Stéphane VANDEVUER
Françoise VAN BAMBEKE
Evelina Colacino
Isabelle Tytgat
Paul Tulkens
Original Assignee
Universite Catholique De Louvain
Universite Libre De Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique De Louvain, Universite Libre De Bruxelles filed Critical Universite Catholique De Louvain
Publication of WO2009080788A2 publication Critical patent/WO2009080788A2/fr
Publication of WO2009080788A3 publication Critical patent/WO2009080788A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Definitions

  • the present application concerns antibacterial agents, processes for the preparation of the disclosed agents, compositions comprising said agents, and uses of said agents including inter alia therapeutic uses.
  • DD-ligases contribute to the synthesis of peptidoglycan, a major component of the bacterial cell wall that is required for bacterial survival.
  • DD-ligases catalyse the synthesis of a dimer of D-amino acids in an early step of peptidoglycan synthesis.
  • DD-ligases catalyse the formation of a dimer of D-alanine (i.e., D-alanine-D- alanine ligases).
  • some DD-ligases can use D-serine or D-lactate instead of one of said two D-alanines to form D-alanine-D-serine dipeptide or D-alanine-D-lactate depsipeptide, respectively.
  • DD-ligases with so-altered specificity can be found in vancomycin- resistant Enterococci (VRE), vancomycin-resistant Staphycoccus aureus, or in some species of lactic bacteria, etc.
  • Vancomycin is an antibiotic commonly used as a last resort treatment for infections caused by multiresistant Enterococci or S. aureus. Because vancomycin acts by binding to the D-AIa-D-AIa motif, bacteria containing DD-ligases capable of employing other substrates such as D-serine or D-lactate can display resistance to vancomycin.
  • D-cycloserine a competitive inhibitor of DD-ligases and of alanine racemase has been used as an antibiotic in the early 1950's and 1960's, but has been largely abandoned due to toxic effects on the central nervous system.
  • the antibiotic activity of D-cycloserine appears to be mainly mediated by inhibition of alanine racemase which converts L-AIa to D-AIa.
  • methylphosphinate inhibitors display high affinity for DD-ligases, but their use as antibiotics is hampered because their high polarity prevents them from crossing the bacterial membrane and reaching their target.
  • More recently described DD-ligase inhibitors include 2-(2-Amino-2- carboxy-ethyl)-1-phenyl-cyclopropanecarboxylic acid, 3-chloro-2,2-dimethyl-N-
  • WO 03/074516 discloses 2-(3-nitrophenyl)-1 ,3-benzoxazole-6- carboxylic acid and 2-(3-aminophenyl)-1 ,3-benzoxazole-6-carboxylic acid as intermediates in a synthesis process, but does not attribute any function to said molecules.
  • 3-(1 ,3-benzoxazol- 2-yl)aniline has been described as antihelmintic but not as an antibacterial agent.
  • the invention addresses the above discussed needs in the art. More specifically, the invention teaches further compounds useful as inhibitors of DD-ligases and as antibacterial agents.
  • the present substances may also entail one or more advantages over previously known DD- ligase inhibitors and/or over existing antibiotics.
  • the compounds can show improved penetration of bacterial cell membrane, for example as compared to methylphosphinate inhibitors, whereby they can more powerfully act on intact, living bacteria.
  • the present molecules are structurally distinct from D-cycloserine and can therefore avoid undesired side effects such as CNS toxicity.
  • the molecules have been designed to act selectively on DD-ligases - since D-amino acids are not naturally encountered in eukaryotic cells, this ensures high degree of specificity of the present compounds to bacteria, thereby further reducing the possibility of unwanted side effects.
  • DD-ligases represent a so far largely unexploited target, it is expected that bacterial resistance to the present compounds in clinics would be minimal. Also, given that the chemical structure and mode of action of the present molecules is considerably different from other antibiotic classes in common use, said molecules would not display cross- resistance with other existing antibiotics, and therefore could target bacteria that have acquired resistance to such existing antibiotics. For example, because the present molecules target DD-ligase and not the D-AIa-D-AIa dimer, they can be effective against both vancomycin-sensitive and vancomycin-resistant bacteria. Also, since DD-ligases are essential enzymes for all bacteria relying on the existence of a cell wall - which encompass most known pathogenic bacteria - the present compounds are expected to show broad spectrum of activity.
  • the invention provides the use of a compound of any of formulas (I- a), (ll-a), (lll-a), (IV-a) or (V-a):
  • the invention provides a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, for use in the treatment of a bacterial infection.
  • a pharmaceutical composition comprising a compound of any of formulas (l-a), (ll-a), (lll-a), (IV- a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, and one or more pharmaceutically acceptable carriers, for use in the treatment of a bacterial infection.
  • Another related aspect provides a method for treating a bacterial infection in a subject in need of such treatment, comprising administering to said subject a therapeutically or prophylactically effective amount of a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof.
  • the invention provides a compound of any of formulas (l-a), (ll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, for use as a medicament.
  • the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-a), (ll-a), (IV-a) or (V-a) as shown above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug or solvate thereof, and one or more pharmaceutically acceptable carriers.
  • the invention also provides a compound of any of formulas (l-a) or (V-a) as shown above, an ⁇ /-oxide form, addition salt, prodrug or solvate thereof.
  • Also provided is a method for inhibition of DD-ligase comprising contacting a DD-ligase, or a composition or a bacterium comprising such, with a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, in an amount sufficient to obtain said inhibition.
  • said DD-ligase inhibition may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
  • said inhibition of DD-ligase may take place in vitro, more particularly encompassing inhibition of isolated DD-ligase, inhibition of isolated DD- ligase when being a part of a composition, as well as inhibition of DD-ligase in bacteria when said bacteria are outside of a human or animal body.
  • isolated when referring to a protein, means that said protein has been identified and separated and/or recovered from a component of its natural environment.
  • an isolated protein can be substantially separated from cellular material or other proteins of a cell source from which it is derived.
  • an isolated protein may be isolated from its natural source or produced recombinantly.
  • Further aspect concerns a method for inhibiting the growth, proliferation and/or survival of bacteria comprising contacting said bacteria with a compound of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a) as shown above, or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, in an amount sufficient to obtain said inhibition.
  • said inhibition of bacterial growth, proliferation and/or survival may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
  • said inhibition of bacterial growth, proliferation and/or survival may take place ex vivo, which refers to treatments of bacteria outside of a human or animal body.
  • ex vivo inhibition may pertain to a method for preserving, disinfecting or sterilising a composition such as for example a liquid solution, device or apparatus contaminated or suspected to be contaminated with bacteria, comprising contacting said composition, device or apparatus with a herein disclosed compound.
  • Exemplary devices or apparatuses to be so disinfected or sterilised may include, without limitation, medical or surgical instruments or appliances, such as for example catheters, prosthetic implants, stents, etc.
  • surfaces of such devices or apparatuses may be disinfected or sterilised by applying a present compound thereto, e.g., in a solution, in a spray aerosol, etc.
  • Exemplary compositions to be so preserved, disinfected or sterilised may include, without limitation, cell culture media for animal cells including inter alia insect or mammalian cells, etc.
  • the growth, proliferation and/or survival of bacteria may be inhibited in an in vitro bacterial cell culture, such as for example to assess the sensitivity of a particular bacterial species, subspecies or strain to present compounds, e.g., in clinical or research settings.
  • R 5 is selected from hydrogen, d_ 6 alkyl, -OR 6 , -SR 6 , -NR 6 R 7 , and d_ 6 alkyl substituted with one or more substituents selected from halo, hydroxy and oxo, R 6 and R 7 are each independently selected from hydrogen, C h alky!, and
  • R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d_ 6 alkyl)amino, d_ 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod_ 6 alkyl, d_ 6 alkyloxy, carboxyl, d_ 6 alkylcarbonyloxy, d_ 6 alkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy and d_ 6 alkyloxy;
  • R 3 is selected from -NHR 10 and nitro,
  • R 10 is selected from hydrogen, d_ 6 alkyl, d_ 6 alkylcarbonyl and d_ 6 alkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d-6alkyloxy;
  • R 4 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d- 6 alkyl)amino, d_ 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod-ealkyl and d_ 6 alkyloxy, each of said groups being optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d_ 6 alkyloxy.
  • the invention provides a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use in the treatment of a bacterial infection.
  • composition comprising a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers, for use in the treatment of a bacterial infection.
  • Another related aspect provides a method for treating a bacterial infection in a subject in need of such treatment, comprising administering to said subject a therapeutically or prophylactically effective amount of a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof.
  • DD-ligase inhibition comprising contacting a DD-ligase, or a composition or a bacterium comprising such, with a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, in an amount sufficient to obtain said inhibition.
  • said DD-ligase inhibition may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
  • said inhibition of DD-ligase may take place in vitro, more particularly encompassing inhibition of isolated DD-ligase, inhibition of isolated DD-ligase when being a part of a composition, as well as inhibition of
  • DD-ligase in bacteria when said bacteria are outside of a human or animal body.
  • Further aspect concerns a method for inhibiting the growth, proliferation and/or survival of bacteria comprising contacting said bacteria with a compound of formula (Vl) wherein p, r, R 1 , R 2 , R 3 and R 4 are as defined above, or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, in an amount sufficient to obtain said inhibition.
  • said inhibition of bacterial growth, proliferation and/or survival may occur in vivo, i.e., within the body of a subject in particular of a human or animal subject.
  • said inhibition of bacterial growth, proliferation and/or survival may take place ex vivo, which refers to treatments of bacteria outside of a human or animal body. Exemplary ex vivo applications are described elsewhere in this application.
  • a sixth group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-b), (ll-b), (lll-b), (IV-b) or (V-b):
  • V-b or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, wherein: p is 0, 1 or 2, preferably p is 0 or 1 , more preferably p is 0; r is 0, 1 or 2, preferably r is 0 or 1 , very preferably r is 0 or very preferably r is 1 ; R 6 is selected from hydrogen, d-ealkyl, and d-ealkyl substituted with one or more substituents selected from halo, hydroxy, Ci_ 6 alkyloxy, carboxyl, Ci_ 6 alkyloxycarbonyl and d-ealkylcarbonyloxy, preferably R 6 is hydrogen or C h alky!, very preferably R 6 is hydrogen or very preferably R 6 is C h alky!; R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(C 1 _ 6 alkyl)amino,
  • a seventh group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-c), (ll-c), (lll-c), (IV-c) or (V-c): or an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemically isomeric form thereof, wherein:
  • R 2 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(Ci-6alkyl)amino, d-ealkylcarbonylamino, d-ealkyl, polyhalod-ealkyl, d-ealkyloxy, carboxyl, d-ealkylcarbonyloxy, d-ealkyloxycarbonyl, each of said groups optionally substituted with one or more substituents selected from halo, hydroxy and Ci_ 6 alkyloxy, preferably R 2 is selected from hydrogen, halo, hydroxy, d-ealkyl, polyhalod_ 6 alkyl and d_ 6 alkyloxy, more preferably R 2 is hydrogen or halo;
  • R 4 is selected from hydrogen, halo, hydroxy, cyano, nitro, amino, mono- or di(d_ 6 alkyl)amino, d- 6 alkylcarbonylamino, d_ 6 alkyl, polyhalod-ealkyl and d_ 6 alkyloxy, each of said groups being optionally substituted with one or more substituents selected from halo, hydroxy, amino, nitro and d- 6 alkyloxy, preferably R 4 is selected from hydrogen, halo, hydroxy, d- 6 alkyl, polyhalod-ealkyl and d-ealkyloxy; more preferably R 4 is hydrogen; R 11 is halo, preferably R 11 is fluoro, chloro, bromo or iodo, more preferably R 11 is bromo; R 12 is d_ 6 alkyl, preferably R 12 is methyl or ethyl, more preferably R 12 is ethyl.
  • An eighth group of preferred compounds of formula (Vl) in the foregoing aspects consists of compounds of any of formulas (l-a), (ll-a), (lll-a), (IV-a) or (V-a), or an ⁇ /-oxide form, addition salt, prodrug or solvate thereof, as defined above wherein.
  • the invention provides a compound of any of formulas (l-b), (ll-b), (IV-b) or (V-b) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use as a medicament.
  • the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-b), (ll-b), (IV-b) or (V-b) as defined above, or a pharmaceutically acceptable N- oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers.
  • the invention provides a compound of any of formulas (l-c), (ll-c), (IV-c) or (V-c) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, for use as a medicament.
  • the invention also provides a pharmaceutical composition comprising a compound of any of formulas (l-c), (ll-c), (IV-c) or (V-c) as defined above, or a pharmaceutically acceptable ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof, and one or more pharmaceutically acceptable carriers.
  • the invention also provides a compound of any of formulas (l-b) or (V-b) as defined above, an ⁇ /-oxide form, addition salt, prodrug, solvate or a stereochemical ⁇ isomeric form thereof.
  • an aspect relates to further compounds capable of establishing bonds with amino acids of DD-ligase enzyme cavity comprising bonds with Glu68, Tyr210 and Arg255 or amino acids equivalent thereto, as well as to uses of such compounds as DD-ligase inhibitors and antibacterial agents, analogously as described herein.
  • the invention also relates to processes for the preparation of the herein disclosed compounds, and particularly compounds of formula (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (lll-c), (IV-c) or (V-c) as defined herein, ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemically isomeric forms thereof, as taught herein.
  • Figure 1 illustrates inhibition of isolated D-alanine-D-alanine ligase (DdI) by the present compounds compared to D-cycloserine.
  • X-axis tested compound.
  • Y-axis residual activity (% of control).
  • Figure 2 illustrates DdI concentration-inhibition relationships for the present compounds ll-a (B), l-a (C) and IV-a (D) compared to D-cycloserine (A).
  • X-axis log[inhibitor] (mM).
  • Y-axis activity of the ligase (%).
  • the Summary section discloses aspects and embodiments of the invention that involve compounds, more particularly compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (lll-c), (IV-c) or (V-c) as defined above, or pharmaceutically acceptable ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemical ⁇ isomeric forms thereof, as well as preferred subgroups of such substances.
  • Ci_ 6 alkyl defines straight- and branched-chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 2-methylpropyl, 2-methyl-butyl, 2-methylpentyl and the like.
  • Polyhalod- ⁇ alkyl defines a Ci-6alkyl as defined herein, wherein two or more hydrogens of said C h alky!
  • substituted denotes that one or more hydrogens on one or more atoms (typically C, N, O or S atoms, usually C atoms) of a group indicated by the modifier "substituted” is replaced with a selection from the recited group, provided that the normal valency of the atoms of the indicated group is not exceeded, and that the substitution results in a chemically stable compound, i.e., a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an useful agent.
  • one or more covers the possibility of one, more or all available atoms of an indicated group to be substituted where appropriate; preferably of one, two or three, more preferably of one or two, and even more preferably of one available atoms of an indicated group to be substituted.
  • addition salt comprises salts which the present compounds are able to form with organic or inorganic bases such as amines, alkali metal bases and earth alkaline metal bases, or quaternary ammonium bases, or with organic or inorganic acids, such as mineral acids, sulfonic acids, carboxylic acids or phosphorus containing acids.
  • organic or inorganic bases such as amines, alkali metal bases and earth alkaline metal bases, or quaternary ammonium bases
  • organic or inorganic acids such as mineral acids, sulfonic acids, carboxylic acids or phosphorus containing acids.
  • addition salt further comprises pharmaceutically acceptable salts, metal complexes and the salts thereof, that the present compounds are able to form.
  • pharmaceutically acceptable salts means pharmaceutically acceptable acid or base addition salts.
  • the pharmaceutically acceptable acid or base addition salts are meant to comprise therapeutically active non-toxic acid and non-toxic base addition salt forms which the present compounds are able to form.
  • the present compounds which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g., hydrochloric or hydrobromic acid, sulphuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e., butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • inorganic acids such as hydrohalic acids, e.g., hydrochloric or hydrobromic acid, sulphuric, nitric, phosphoric and the like acids
  • organic acids such as, for example,
  • the present compounds which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base.
  • suitable organic or inorganic base e.g., the ammonium salts, the alkali and earth alkaline metal salts, e.g., the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g., the benzathine, N- methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • acid or base addition salt also comprise the hydrates and the solvent addition forms thereof which the present compounds are able to form. Examples of such forms are, e.g., hydrates, alcoholates and the like.
  • metal complexes means a complex formed between a present compound and one or more organic or inorganic metal salt or salts.
  • organic or inorganic salts comprise the halogenides, nitrates, sulfates, phosphates, acetates, trifluoroacetates, trichloroacetates, propionates, tartrates, sulfonates, e.g., methylsulfonates, 4-methylphenylsulfonates, salicylates, benzoates and the like of the metals of the second main group of the periodical system, e.g., the magnesium or calcium salts, of the third or fourth main group, e.g., aluminium, tin, lead, as well as the first to the eighth transition groups of the periodical system such as, for example, chromium, manganese, iron, cobalt, nickel, copper, zinc and the like.
  • stereochemically isomeric forms of present compounds as used herein, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the present compounds may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the present compounds both in pure form or in admixture with each other are intended to be embraced.
  • stereoisomerically pure concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e., minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e., 100% of one isomer and none of the other), more preferably, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more preferably having a stereoisomeric excess of 94% up to 100% and most preferably having a stereoisomeric excess of 97% up to 100%.
  • enantiomerically pure and “diastereomerically pure” should be understood in a similar way, but then having regard to the enantiomeric excess and the diastereomeric excess of the mixture in question, respectively.
  • the ⁇ /-oxide forms of the present compounds are meant to comprise those compounds wherein one or several nitrogen atoms are oxidized to the so-called ⁇ /-oxide.
  • the present compounds may form solvates, for example, with water (i.e., hydrates) or common organic solvents.
  • solvate means a physical association of the present compounds with one or more solvent molecules. This physical association involves varying degrees of ionic and other bonding, including hydrogen bonding.
  • solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • solvate is intended to encompass both solution-phase and isolatable solvates.
  • suitable solvates include ethanolates, methanolates, and the like.
  • the present compounds may have one or more crystalline or amorphous polymorph forms, as such intended to be embraced.
  • isotopes of atoms present in the present compounds include tritium and deuterium and isotopes of carbon include
  • Prodrugs of the present compounds are substances that readily undergo chemical changes under physiological conditions (in vivo) to provide the present compounds. Additionally, prodrugs can be converted to the present compounds by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the present compounds when placed in a trans-dermal patch reservoir with a suitable enzyme or chemical reagent.
  • prodrug means pharmacologically acceptable derivatives such as, e.g., esters, amides and phosphates, such that the resulting in vivo biotransformation product of the derivative are the active compounds as defined above.
  • Prodrugs of the present compounds are prepared by modifying functional groups present in a compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo or ex vivo, to the parent compound.
  • Prodrugs may include substances wherein a hydroxy group or an amino group is bonded to any group that, when the prodrug is administered to a patient, cleaves to form a free hydroxyl or free amino, respectively.
  • prodrugs are described for instance in WO 99/33795, WO 99/33815, WO 99/33793 and WO 99/33792 all incorporated herein by reference. Prodrugs are usually characterised by excellent aqueous solubility, increased bioavailability and are readily metabolised into the active inhibitors in vivo.
  • the term "present compounds” is meant to include also the N- oxide forms, the acid or base addition salts particularly the pharmaceutically acceptable acid or base addition salts, the prodrugs, the solvates and all stereoisomeric forms of the compounds as defined in the Summary section, more particularly of compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (ll-c), (III- c), (IV-c) or (V-c) as defined above, or compounds of any preferred subgroups thereof.
  • the compounds of formula (Vl) wherein R 3 is -NH 2 herein termed compounds of formula (Vl- i) can be prepared from compounds of formula (Vl) wherein R 3 is -NO 2 , herein termed compounds of formula (Vl-ii), by a nitro to amine reduction reaction, for example in the presence of a metal catalyst such as Raney Nickel and an appropriate reductant such as hydrogen, or using sodium dithionite or another suitable reducing agent, in a suitable solvent such as methanol or ethanol:
  • the compounds of formula (Vl) can also be prepared from intermediates of formula (IX) by cyclocondensation at elevated temperatures in the presence of a suitable acid catalyst such as HCI or p-toluenesulfonic acid in an appropriate solvent such ethanol: (IX)
  • Intermediates of formula (IX) can be prepared from intermediates of formula (Xl) by demethylation such as using boron tribromide (BBr 3 ) in a suitable solvent such as dichloromethane:
  • any of the processes for preparation of the present compounds and intermediates it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protecting Groups, P. Kocienski, Thieme Medical Publishers,
  • the protecting groups may be removed at a convenient subsequent stage using methods known in the art.
  • suitable solvents which may be readily selected by one of skill in the art of organic synthesis, said suitable solvents generally being any solvent which is substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which may range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction may be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step may be selected.
  • intermediates and/or final compounds may, if necessary for the following steps and/or for monitoring the reaction, be worked-up and/or purified by methods known in the field of organic synthetic chemistry, such as filtering, solvent extraction, solvent evaporation by heat or under vacuum, re-crystallisation, trituration, chromatography or a method using an ion exchange resin.
  • the present compounds represent useful antibacterial agents, i.e., substances which are destructive to or prevent the growth of bacteria, particularly suitable for the treatment of bacterial infections in subjects in need thereof.
  • the present compounds are also suitable for inhibiting the growth, proliferation and/or survival of bacteria in vivo (i.e., within a subject's body), as well as in ex vivo (i.e., outside of a subject's body) situations.
  • subject refers to animals, preferably warm-blooded animals, more preferably vertebrates, and even more preferably mammals specifically including humans and non-human mammals, that have been the object of treatment, observation or experiment.
  • mamal includes any animal classified as such, including, but not limited to, humans, domestic and farm animals, zoo animals, sport animals, pet animals, companion animals and experimental animals, such as, for example, mice, rats, hamsters, rabbits, dogs, cats, guinea pigs, cattle, cows, sheep, horses, pigs and primates, e.g., monkeys and apes.
  • Preferred patients are human subjects, including both genders and all age categories thereof.
  • a phrase such as "a subject in need of treatment” includes subjects that would benefit from treatment of a given condition, particularly of a bacterial infection. Such subjects may include, without limitation, those that have been diagnosed with said condition, those prone to contract or develop said condition and/or those in whom said condition is to be prevented.
  • treat encompass both the therapeutic treatment of an already developed disorder, such as the therapy of an already developed bacterial infection, as well as prophylactic or preventative measures, wherein the aim is to prevent or lessen the chances of incidence of an undesired affliction, such as to prevent the chances of contraction and progression of a bacterial infection.
  • beneficial or desired clinical results may include, without limitation, alleviation of one or more symptoms or one or more biological markers (e.g., fever, bacterial load, etc.), diminishment of extent of disease, stabilised (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and the like.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • prophylactically effective amount refers to an amount of an active compound or pharmaceutical agent that inhibits or delays in a subject the onset of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician.
  • therapeutically effective amount refers to an amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a subject that is being sought by a researcher, veterinarian, medical doctor or other clinician, which may include inter alia alleviation of the symptoms of the disease or disorder being treated. Methods are known in the art for determining therapeutically and prophylactically effective doses for the present compounds.
  • bacterial infection refers to the entry and proliferation of a bacterium that is pathogenic to a subject in a bodily tissue of said subject, producing subsequent tissue injury and disease.
  • the term also encompasses a "bacterial superinfection" which refers to a secondary infection that occurs after a previous infection; this secondary infection is generally more destructive than the first and is often attributed to bacteria which have become resistant to the antibiotics used to treat the first infection.
  • the terms also encompass nosocomial, i.e., hospital-acquired bacterial infections and/or superinfections. The present compounds can reduce bacterial infections and/or superinfections and prevent further infection from developing.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria comprise DD-ligase activity.
  • DD-ligase refers to a class of enzymes which catalyse the formation of a dimer of D-amino acids from the corresponding monomers at the expense of ATP.
  • the term encompasses D-alanine-D-alanine ligases (EC 6.3.2.4) which catalyse the reaction ATP + 2 D-alanine — > ADP + phosphate + D- alanyl-D-alanine.
  • DD-ligases which can employ other D-amino acid substrates, such as for example D-alanine-D-serine ligases and D-alanine-D-lactate ligases.
  • D-amino acid substrates such as for example D-alanine-D-serine ligases and D-alanine-D-lactate ligases.
  • the presence of DD-ligase activity in bacteria or lysates thereof may be tested in known enzymatic assays, such as ones analogous to that shown in the examples.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria comprise peptidoglycan.
  • peptidoglycan refers to a glycopeptide polymer that is a component of bacterial cell walls, and is generally characterised as comprising ⁇ -(1 ,4) linked N-acetylglucosamine (NAG) and N- acetylmuramic acid chains cross-linked by oligopeptide units comprising D-amino acids.
  • NAG N-acetylglucosamine
  • the present compounds can advantageously interfere with the synthesis of peptidoglycan and hence combat bacteria comprising such.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are Gram-positive bacteria, Gram-negative bacteria, aerobic bacteria, anaerobic bacteria or mycobacteria.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are Gram-positive bacteria. Due to high peptidoglycan content in Gram-positive bacteria, the present compounds which inhibit peptidoglycan synthesis may be particularly effective in said bacteria.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are chosen, by preference but without limitation, from the genera
  • Acinetobacter Bacillus, Bacteroides, Campylobacter, Clostridium, Corynebacterium,
  • Klebsiella Legionella, Listeria, Moraxella, Mycobacterium, Mycoplasma, Neisseria, Porphyromonas, Prevotella, Proteus, Pseudomonas, Salmonella, Serratia, Staphylococcus,
  • Streptococcus and Vibrio, particularly wherein said bacteria represent pathogenic species of said genera.
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are chosen, by preference but without limitation, from Staphylococcus aureus; Staphylococcus epidermidis and other coagulase-negative staphylococci; Streptococcus pyogenes; Streptococcus pneumoniae; Streptococcus agalactiae; Enterococcus species; Corynebacterium diphtheriae; Listeria monocytogenes; Bacillus anthracis; Neisseria meningitidis; Neisseria gonorrhoeae; Moraxella catarrhalis; Vibrio cholerae; Campylobacter jejuni; Enterobacteriaceae (including Escherichia, Salmonella, Klebsiella, Enterobacter); Pseudomonas aeruginosa; Acinetobacter species; Ha
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are resistant to other inhibitors of cell wall synthesis, such as particularly to ⁇ -lactam antibiotics (e.g., penicillins, cephalosporins) or to vancomycin.
  • ⁇ -lactam antibiotics e.g., penicillins, cephalosporins
  • vancomycin vancomycin
  • the present compounds may be employed for the treatment of infections caused by bacteria, or for inhibiting the growth, proliferation and/or survival of bacteria, wherein said bacteria are vancomycin-sensitive or vancomycin-resistant.
  • vancomycin-resistant bacteria that may be inhibited include, without limitation, vancomycin- resistant Staphylococcus aureus, Staphylococcus epidermis, vancomycin-resistant Enterococci such as for example vancomycin-resistant Enterococcus faecalis, Enterococcus faecium, Enterococcus casseliflavus and Enterococcus gallinarum, and vancomycin-resistant Clostridium innocuum.
  • the present compounds may also represent useful inhibitors of DD-ligases as defined above.
  • the term “inhibition” encompasses any extent of inhibition of DD-ligase activity, in particular of its enzymatic activity, such as, e.g., inhibition by at least about 10%, by at least about 20%, by at least about 30%, by at least about 40%, by at least about 50%, by at least about 60%, by at least about 70%, by at least about 80%, by at least about 90%, or even by about 100%, compared to DD-ligase activity in the absence of the inhibitor.
  • the extent of DD-ligase inhibition may be measured by assays known in the art, such as described in the examples.
  • the present compounds may be advantageously formulated as pharmaceutical formulations for treating bacterial infections.
  • compositions comprise one or more present compounds or pharmaceutically acceptable N-oxide forms, acid or base addition salts, prodrugs, solvates or stereoisomeric forms thereof (i.e., one or more "active substances"), and one or more pharmaceutically acceptable carrier/excipient.
  • carrier or “excipient” includes any and all solvents, diluents, buffers (such as, e.g., neutral buffered saline or phosphate buffered saline), solubilisers, colloids, dispersion media, vehicles, fillers, chelating agents (such as, e.g., EDTA or glutathione), amino acids (such as, e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavourings, aromatisers, thickeners, agents for achieving a depot effect, coatings, antifungal agents, preservatives, antioxidants, tonicity controlling agents, absorption delaying agents, and the like.
  • buffers such as, e.g., neutral buffered saline or phosphate buffered saline
  • solubilisers such as, e.g., EDTA or glutathi
  • Illustrative, non-limiting carriers for use in formulating the pharmaceutical compositions include, for example, oil-in-water or water-in-oil emulsions, aqueous compositions with or without inclusion of organic co-solvents suitable for intravenous (IV) use, liposomes or surfactant-containing vesicles, microspheres, microbeads and microsomes, powders, tablets, capsules, suppositories, aqueous suspensions, aerosols, and other carriers apparent to one of ordinary skill in the art.
  • compositions of the invention may be formulated for essentially any route of administration, such as without limitation, oral administration (such as, e.g., oral ingestion or inhalation), intranasal administration (such as, e.g., intranasal inhalation or intranasal mucosal application), parenteral administration (such as, e.g., subcutaneous, intravenous, intramuscular, intraperitoneal or intrasternal injection or infusion), transdermal or transmucosal (such as, e.g., oral, sublingual, intranasal) administration, topical administration, rectal, vaginal or intra-tracheal instillation, and the like.
  • oral administration such as, e.g., oral ingestion or inhalation
  • intranasal administration such as, e.g., intranasal inhalation or intranasal mucosal application
  • parenteral administration such as, e.g., subcutaneous, intravenous, intramuscular
  • compositions of the invention can be, for example, systemic, local, tissue-specific, etc., depending of the specific needs of a given application of the invention.
  • pharmaceutical compositions may be formulated in the form of pills, tablets, lacquered tablets, coated (e.g., sugar-coated) tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions.
  • preparation of oral dosage forms may be is suitably accomplished by uniformly and intimately blending together a suitable amount of the active compound in the form of a powder, optionally also including finely divided one or more solid carrier, and formulating the blend in a pill, tablet or a capsule.
  • solid carriers include calcium phosphate, magnesium stearate, talc, sugars (such as, e.g., glucose, mannose, lactose or sucrose), sugar alcohols (such as, e.g., mannitol), dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Compressed tablets containing the pharmaceutical composition can be prepared by uniformly and intimately mixing the active ingredient with a solid carrier such as described above to provide a mixture having the necessary compression properties, and then compacting the mixture in a suitable machine to the shape and size desired.
  • Moulded tablets maybe made by moulding in a suitable machine, a mixture of powdered compound moistened with an inert liquid diluent.
  • Suitable carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc.
  • compositions may be formulated with illustrative carriers, such as, e.g., as in solution with saline, polyethylene glycol or glycols, DPPC, methylcellulose, or in mixture with powdered dispersing agents, further employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.
  • illustrative carriers such as, e.g., as in solution with saline, polyethylene glycol or glycols, DPPC, methylcellulose, or in mixture with powdered dispersing agents, further employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.
  • Suitable pharmaceutical formulations for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the compounds of the invention or their physiologically tolerable salts in a pharmaceutically acceptable solvent, such as ethanol or water, or a mixture of such solvents.
  • a pharmaceutically acceptable solvent such as ethanol or water, or a mixture of such solvents.
  • the formulation can also additionally contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers as well as a propellant.
  • delivery may be by use of a single-use delivery device, a mist nebuliser, a breath-activated powder inhaler, an aerosol metered-dose inhaler (MDI) or any other of the numerous nebuliser delivery devices available in the art.
  • MDI aerosol metered-dose inhaler
  • mist tents or direct administration through endotracheal tubes may also be used.
  • carriers for administration via mucosal surfaces depend upon the particular route, e.g., oral, sublingual, intranasal, etc.
  • illustrative examples include pharmaceutical grades of mannitol, starch, lactose, magnesium stearate, sodium saccharide, cellulose, magnesium carbonate and the like, with mannitol being preferred.
  • illustrative examples include polyethylene glycol, phospholipids, glycols and glycolipids, sucrose, and/or methylcellulose, powder suspensions with or without bulking agents such as lactose and preservatives such as benzalkonium chloride, EDTA.
  • the phospholipid 1 ,2 dipalmitoyl-sn- glycero-3-phosphocholine (DPPC) is used as an isotonic aqueous carrier at about 0.01-0.2% for intranasal administration of the compound of the subject invention at a concentration of about 0.1 to 3.0 mg/ml.
  • compositions may be advantageously formulated as solutions, suspensions or emulsions with suitable solvents, diluents, solubilisers or emulsifiers, etc.
  • suitable solvents are, without limitation, water, physiological saline solution or alcohols, e.g. ethanol, propanol, glycerol, in addition also sugar solutions such as glucose, invert sugar, sucrose or mannitol solutions, or alternatively mixtures of the various solvents mentioned.
  • the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally-acceptable diluents or solvents such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable dispersing or wetting and suspending agents such as sterile, bland, fixed oils, including synthetic
  • a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP Water for Injection (WFI).
  • Other illustrative carriers for intravenous use include 10% USP ethanol and USP WFI; 0.01-0.1 % triethanolamine in USP WFI; or 0.01- 0.2% dipalmitoyl diphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral vegetable oil-in-water emulsion.
  • Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01-0.1 % triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, or a 1 to 2 or 1 to 4 mixture of 10% USP ethanol, 40% propylene glycol and the balance an acceptable isotonic solution such as 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI and 1 to 10% squalene or parenteral vegetable oil-in-water emulsions.
  • PBS phosphate buffered saline
  • aqueous formulations may comprise one or more surfactants.
  • the composition can be in the form of a micellar dispersion comprising at least one suitable surfactant, e.g., a phospholipid surfactant.
  • phospholipids include diacyl phosphatidyl glycerols, such as dimyristoyl phosphatidyl glycerol (DPMG), dipalmitoyl phosphatidyl glycerol (DPPG), and distearoyl phosphatidyl glycerol (DSPG), diacyl phosphatidyl cholines, such as dimyristoyl phosphatidylcholine (DPMC), dipalmitoyl phosphatidylcholine (DPPC), and distearoyl phosphatidylcholine (DSPC); diacyl phosphatidic acids, such as dimyristoyl phosphatidic acid (DPMA), dipahnitoyl phosphatidic acid (DPPA), and distearoyl phosphatidic acid (DSPA); and diacyl phosphatidyl ethanolamines such as dimyristoyl phosphatidyl ethanolamine (DPME), dipalmitoyl phosphatid
  • a surfactant: active substance molar ratio in an aqueous formulation will be from about 10:1 to about 1 :10, more typically from about 5:1 to about 1 :5, however any effective amount of surfactant may be used in an aqueous formulation to best suit the specific objectives of interest.
  • these formulations may be prepared by mixing the compounds according to the invention with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
  • the present active substances may be used alone or in combination with any antimicrobial therapies and antibiotics known in the art ("combination therapy").
  • Combination therapies as contemplated herein may comprise the administration of at least one active substance of the present invention and at least one other pharmaceutically or biologically active ingredient.
  • Said present active substance(s) and said pharmaceutically or biologically active ingredient(s) may be administered in either the same or different pharmaceutical formulation(s), simultaneously or sequentially in any order.
  • antibiotics in combination therapy with which the present active substances may be employed include, without limitation, ⁇ -lactam antibiotics (such as, e.g., penicillins and cephalosporins), sulfonamide antibiotics, aminoglycoside antibiotics, carbapenems, trimethoprim, chloramphenicol, glycopeptide antibiotics such as vancomycin, macrolides, quinoline antibiotics, tetracyclines, etc.
  • ⁇ -lactam antibiotics such as, e.g., penicillins and cephalosporins
  • sulfonamide antibiotics aminoglycoside antibiotics
  • carbapenems trimethoprim
  • chloramphenicol chloramphenicol
  • glycopeptide antibiotics such as vancomycin, macrolides, quinoline antibiotics, tetracyclines, etc.
  • the dosage or amount of the present active substances used, optionally in combination with one or more other active compound to be administered, depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, body weight, general health, diet, mode and time of administration, and individual responsiveness of the human or animal to be treated, on the route of administration, efficacy, metabolic stability and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to the agent(s) of the invention.
  • a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg of body weight or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • a preferred dosage of the active substance of the invention may be in the range from about 0.05 mg/kg to about 10 mg/kg of body weight.
  • one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
  • Such doses may be administered intermittently, e.g., every week or every three weeks.
  • This invention also provides a method for treating or protecting plants from bacterial infection by applying an effective amount of the present compounds to the foliage, roots or the soil surrounding the plants or roots.
  • said plants may be treated with compounds of any of formulas (Vl), (l-a), (ll-a), (lll-a), (IV-a), (V-a), (l-b), (ll-b), (lll-b), (IV-b), (V-b), (l-c), (II- c), (I I l-c), (IV-c) or (V-c) as defined above, or ⁇ /-oxide forms, addition salts, prodrugs, solvates or stereochemical ⁇ isomeric forms thereof, as well as preferred subgroups of such substances.
  • the present compounds can be combined with known pesticides or insecticides.
  • Suitable formulations will be known to those skilled in the art.
  • compounds within the present invention when used to treat or protect plants from antibiotic resistant bacterial infections can be formulated as wettable powders, granules and the like, or can be microencapsulated in a suitable medium and the like.
  • examples of other formulations include, but are not limited to soluble powders, wettable granules, dry flowables, aqueous flowables, wettable dispersible granules, emulsifiable concentrates and aqueous suspensions.
  • Other suitable formulations will be known to those skilled in the art.
  • Escherichia coli LMG 194 (Invitrogen) was the host strain for recombinant plasmids.
  • Total DNA from Enterococcus faecalis JH2-2 (Jacob & Hobbs 1974. J Bacteriol 117: 360-372) was prepared as described (Le Bouguenec et al. 1990. J Bacteriol 172: 727-734) and D-AIa-D-AIa gene was amplified by PCR using the pfu polymerase (Promega) and the primers 1 and 2
  • the resulting plasmid encodes for Ddl-His6 protein under the control of a L-arabinose inducible promoter (Guzman et al. 1995. J Bacteriol 177: 4121-4130). Constructed plasmid was transformed into compete strain of LMG194 E. coli for expression.
  • the cultures were centrifuged 15 minutes at 4000 rpm and cell pellets were resuspended in cold buffer A (Buffer A : Hepes 50 mM pH 8.0, MgCI 2 5mM, imidazole 10 mM, glycerol 10%) by concentring 2Ox. All following steps of purification were performed in 4°C. Bacteria were disrupted twice by passage in a French Press (operated at 1000 psi) and centrifuged at 18000 g during 30 min.
  • Buffer A Hepes 50 mM pH 8.0, MgCI 2 5mM, imidazole 10 mM, glycerol 10%
  • HisLink resin Promega
  • HisLink resin Promega
  • Lysate was removed and the resin was placed on a column and washed with buffer A (30 ml of buffer A for 5 ml of HisLink slurry).
  • His- tagged proteins were eluted by adding buffer B (10 ml for 5 ml of HisLink slurry) ( Buffer B : Hepes 50 mM pH 8.0, MgCI2 5mM, NaCI 300 mM, imidazole 500 mM, glycerol 10%).
  • Elution fraction was dialysed twice (for 2h and overnight) against buffer C (Buffer C : Hepes 50 mM pH 7.2, KCI 15O mM, MgCI2 5 mM, GSH 5 mM and glycerol 20% ; 2 L of buffer C for 150ml of elution buffer).
  • buffer C Buffer C : Hepes 50 mM pH 7.2, KCI 15O mM, MgCI2 5 mM, GSH 5 mM and glycerol 20% ; 2 L of buffer C for 150ml of elution buffer.
  • proteins fractions were analyzed for purity by SDS- polyacrylamide gel electrophoresis (Novex tris-Glycine Gels 14%, Invitrogen); one unique band was obtained at -42 kDa. Protein concentrations were determined by the method of Bradford using bovine serum albumin as standard (Quick Start Bradford Protein Assay, BioRad). Pure fractions are stored in buffer C at -80 0
  • Activity of the His-tagged DdI ligase was determined by measuring the quantity of D- AIa-D- AIa produced from D-AIa using D-[ 14 C]AIa.
  • Assay mixtures (10 ⁇ l) contained Tris-HCI 20 mM pH 7.4, MgCI2 10 mM, KCI 10 mM, ATP 5 mM, enzyme ( 0.1 to 3 ⁇ g) and mixture of D-[1- 14 C]AIa 10 mM (Moravek: 51 mCi/mmol, 0.1 mCi/ml) and unlabeled D-AIa to a final concentration of 10 mM at 0.02 ⁇ Ci.
  • molecules for testing the effect of inhibitors, molecules (at suitable concentration(s)) were preincubated for 5 min with the enzyme in the above assay mixture before addition of ATP and D-[ 14 C]AIa (in a volume of 20 ⁇ l). Depending of the water-solubility of each inhibitor, up to 10% of DMSO was added in reaction buffer. The mixture was incubated 30 min at 30 0 C. The reaction was stopped by boiling the samples for 5 min (immersion in a water bath set at 100 0 C), and centrifuged 10 min at 13,000 rpm.
  • the corresponding fragments were used for determination of their radioactivity by placing them in vials containing 10 ml of scintillation mixture (Ultima Gold from PerkinElmer) and by counting samples in a Packard TriCarb Liquid scintillation analyser (1900TR) with an efficiency of 95%.
  • scintillation mixture Ultima Gold from PerkinElmer
  • the percentage of conversion of D-AIa into the dimmer was calculated, and enzyme activity expressed as moles of product released per minute and per mg of enzyme.
  • D-AIa-D-AIa ligase has been purified from Enterococcus faecalis JH2-2. More than 1 g has been obtained from 12 L of induced bacterial culture with a purification factor of about 2 and a yield of about 65%. The activity of the pure enzyme was about 1.5 nmol/min/ ⁇ g at 30 0 C.
  • the invention also relates to a process for preparation of a compound of any of formula (l-a), (ll-a), (lll-a) (IV-a) and (V-a) as taught in above schemes 1 , 2, 3, 4 and 5, respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des composés utilisés comme agents antibactériens, des processus permettant de les préparer, et des compositions comprenant lesdits agents, lesdits composés étant de formule (VI) et r, p, R1, R2, R3 et R4 ayant les significations énoncées.
PCT/EP2008/068100 2007-12-21 2008-12-19 Agents antibactériens WO2009080788A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07150355 2007-12-21
EP07150355.1 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009080788A2 true WO2009080788A2 (fr) 2009-07-02
WO2009080788A3 WO2009080788A3 (fr) 2010-05-20

Family

ID=39744739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/068100 WO2009080788A2 (fr) 2007-12-21 2008-12-19 Agents antibactériens

Country Status (1)

Country Link
WO (1) WO2009080788A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104788398A (zh) * 2015-03-24 2015-07-22 上海交通大学 苯并恶唑类化合物及其制备方法和用途
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074516A1 (fr) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Derives d'acides carboxyliques phtalimidiques
EP1571142A1 (fr) * 2004-03-01 2005-09-07 Rottapharm S.p.A. Dérivés de type amidine hétérocyclique anti-inflammatoires et analgétiques, inhibiteurs de la production de monoxide d'azote (NO)
WO2007042816A1 (fr) * 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles convenant pour le traitement d'une inflammation
WO2007091106A2 (fr) * 2006-02-10 2007-08-16 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074516A1 (fr) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Derives d'acides carboxyliques phtalimidiques
EP1571142A1 (fr) * 2004-03-01 2005-09-07 Rottapharm S.p.A. Dérivés de type amidine hétérocyclique anti-inflammatoires et analgétiques, inhibiteurs de la production de monoxide d'azote (NO)
WO2007042816A1 (fr) * 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles convenant pour le traitement d'une inflammation
WO2007091106A2 (fr) * 2006-02-10 2007-08-16 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104788398A (zh) * 2015-03-24 2015-07-22 上海交通大学 苯并恶唑类化合物及其制备方法和用途
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US11208391B2 (en) 2018-03-13 2021-12-28 Azad Pharma Ag Polymorphs and new path to synthesize Tafamidis
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof

Also Published As

Publication number Publication date
WO2009080788A3 (fr) 2010-05-20

Similar Documents

Publication Publication Date Title
ES2257296T3 (es) Nuevas prolinas como agentes antimicrobianos.
TWI374138B (en) 5-hydroxymethyl-oxazolidin-2-one derivatives
EP2203219B1 (fr) Benzamidines substituées utilisées comme agents antibactériens
KR20070063546A (ko) 비만증 치료를 위한 비페닐-4-일-카르보닐아미노산유도체의 제조법 및 용도
TW201249849A (en) Selective glycosidase inhibitors and uses thereof
JP2007505950A (ja) β−ラクタマーゼ阻害剤およびその使用方法
AU2004258821A1 (en) Antibacterial methods and compositions
US20150051275A1 (en) Antibacterial agents: sidechainfluorinated myxopyronin derivatives
WO2012037508A2 (fr) Agents antibactériens : dérivés de myxopyronine de puissance élevée
EP3180317A1 (fr) Inhibiteurs du facteur xia
EP2725029A1 (fr) Nouveaux composés antibactériens et leurs applications biologiques
EP3247354B1 (fr) Inhibiteurs du factor xia
US20130296421A1 (en) Arylpropionyl-alpha-pyrone antibacterial agents
WO2011081945A2 (fr) Activation et activateurs de sirt6
WO2013103969A1 (fr) Agents antibactériens : dérivés du phloroglucinol
CN108137574B (zh) 羟烷基噻二唑衍生物
WO2009080788A2 (fr) Agents antibactériens
WO2012017434A2 (fr) Composés destinés au traitement d'infections bactériennes
EP1280808A1 (fr) Antibiotiques de la famille des beta-lactamines ameliores
WO2008094507A2 (fr) Nouveaux composés de fusion
US20110086813A1 (en) Compounds for treating bacterial infections
KR910000440B1 (ko) 이미다조[1,5-a]피리딘 유도체의 제조방법
US9282738B2 (en) Antimicrobial compositions and methods of use thereof
US10450292B2 (en) Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
CN112118837B (zh) 抗菌剂：o-烷基氘化派洛宁

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08863521

Country of ref document: EP

Kind code of ref document: A2